{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:40:43Z","timestamp":1792608043382,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of B-cell malignancies but have not yet succeeded in acute myeloid leukemia (AML), largely due to the lack of cell surface antigens that can distinguish leukemia cells from essential normal hematopoietic stem cells (HSCs). Here, we used a newly developed high-affinity monoclonal antibody (mAb) B16, which is specific for the surface ROR2 in both human and mouse. Although ROR2 is a developmentally restricted protein that is primarily expressed during embryogenesis, we find that ROR2 protein is generally expressed by AML cells, including leukemia stem cells (LSCs), in patients with adverse-risk disease. Consistently, ROR2 is undetectable in most normal postnatal tissues and HSCs. Additionally, ROR2 can activate STAT3 signaling in response to Wnt11 in AML. Employing the binding domain of the anti-ROR2 mAb, we generated anti-ROR2 CAR T cells that selectively eliminated ROR2-positive AML cells of these patients while sparing normal HSCs. Intravenous infusion of such anti-ROR2 CAR T cells into immune-deficient mice selectively eradicated engrafted ROR2-positive human AML cells, including LSCs, without adversely affecting non-neoplastic normal mouse tissues or hematopoiesis. We propose that anti-ROR2 CAR T cells may offer therapeutic benefit for AML patients.<\/jats:p>","DOI":"10.1038\/s41417-026-01087-8","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:55:45Z","timestamp":1792601745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ROR2-expressing acute myelogenous leukemia cells can be selectively targeted by anti-ROR2 CAR T cells"],"prefix":"10.1038","author":[{"given":"Yimeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7192-6429","authenticated-orcid":false,"given":"Zhenghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9443-7747","authenticated-orcid":false,"given":"Chao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiluan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-9917","authenticated-orcid":false,"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu J.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8348-8755","authenticated-orcid":false,"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4118-362X","authenticated-orcid":false,"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6872-2665","authenticated-orcid":false,"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0564-895X","authenticated-orcid":false,"given":"Suping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"1087_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","journal-title":"Lancet"},{"key":"1087_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1200\/JCO.2010.30.2554","volume":"29","author":"G Marcucci","year":"2011","unstructured":"Marcucci G, Haferlach T, D\u00f6hner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29:475\u201386.","journal-title":"J Clin Oncol"},{"key":"1087_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645\u20138.","journal-title":"Nature"},{"key":"1087_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/ajh.25214","volume":"93","author":"EH Estey","year":"2018","unstructured":"Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93:1267\u201391.","journal-title":"Am J Hematol"},{"key":"1087_CR5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s12015-021-10308-6","volume":"18","author":"NA Long","year":"2022","unstructured":"Long NA, Golla U, Sharma A, Claxton DF. Acute myeloid leukemia stem cells: origin, characteristics, and clinical implications. Stem Cell Rev Rep. 2022;18:1211\u201326.","journal-title":"Stem Cell Rev Rep"},{"key":"1087_CR6","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730\u20137.","journal-title":"Nat Med"},{"key":"1087_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101108","volume":"4","author":"AL Boyd","year":"2023","unstructured":"Boyd AL, Lu J, Hollands CG, Alsostovar L, Murali S, Reid JC, et al. Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia. Cell Rep Med. 2023;4:101108.","journal-title":"Cell Rep Med"},{"key":"1087_CR8","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2005-06-2325","volume":"107","author":"DJ Pearce","year":"2006","unstructured":"Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C, et al. AML engraftment in the NOD\/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006;107:1166\u201373.","journal-title":"Blood"},{"key":"1087_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, D\u00edaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10:210.","journal-title":"Signal Transduct Target Ther"},{"key":"1087_CR10","doi-asserted-by":"publisher","first-page":"26181","DOI":"10.1016\/S0021-9258(18)35733-8","volume":"267","author":"P Masiakowski","year":"1992","unstructured":"Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem. 1992;267:26181\u201390.","journal-title":"J Biol Chem"},{"key":"1087_CR11","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.1073\/pnas.90.15.7109","volume":"90","author":"C Wilson","year":"1993","unstructured":"Wilson C, Goberdhan DC, Steller H. Dror, a potential neurotrophic receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of Trk-related receptor tyrosine kinases. Proc Natl Acad Sci USA 1993;90:7109\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1087_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s004270100140","volume":"211","author":"R Al-Shawi","year":"2001","unstructured":"Al-Shawi R, Ashton SV, Underwood C, Simons JP. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev Genes Evol. 2001;211:161\u201371.","journal-title":"Dev Genes Evol"},{"key":"1087_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1081\/RRS-120018757","volume":"23","author":"A Yoda","year":"2003","unstructured":"Yoda A, Oishi I, Minami Y. Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J Recept Signal Transduct Res. 2003;23:1\u201315.","journal-title":"J Recept Signal Transduct Res"},{"key":"1087_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/25168657211064232","volume":"15","author":"R Guo","year":"2022","unstructured":"Guo R, Xing QS. Roles of Wnt signaling pathway and ROR2 receptor in embryonic development: an update review article. Epigenet Insights. 2022;15:25168657211064232.","journal-title":"Epigenet Insights"},{"key":"1087_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2015.01.010","volume":"150","author":"Z Debebe","year":"2015","unstructured":"Debebe Z, Rathmell WK. Ror2 as a therapeutic target in cancer. Pharm Ther. 2015;150:143\u20138.","journal-title":"Pharm Ther"},{"key":"1087_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep12991","volume":"5","author":"J Huang","year":"2015","unstructured":"Huang J, Fan X, Wang X, Lu Y, Zhu H, Wang W, et al. High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma. Sci Rep. 2015;5:12991.","journal-title":"Sci Rep"},{"key":"1087_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1158\/1541-7786.MCR-15-0484","volume":"14","author":"O Lyros","year":"2016","unstructured":"Lyros O, Nie L, Moore T, Medda R, Otterson M, Behmaram B, et al. Dysregulation of WNT5A\/ROR2 signaling characterizes the progression of Barrett-associated esophageal adenocarcinoma. Mol Cancer Res. 2016;14:647\u201359.","journal-title":"Mol Cancer Res"},{"key":"1087_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41375-019-0486-9","volume":"34","author":"M Frenquelli","year":"2020","unstructured":"Frenquelli M, Caridi N, Antonini E, Storti F, Vigan\u00f2 V, Gaviraghi M, et al. The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation. Leukemia. 2020;34:257\u201370.","journal-title":"Leukemia"},{"key":"1087_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1172\/JCI83535","volume":"126","author":"J Yu","year":"2016","unstructured":"Yu J, Chen L, Cui B, Widhopf GF 2nd, Shen Z, Wu R, et al. Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Investig. 2016;126:585\u201398.","journal-title":"J Clin Investig"},{"key":"1087_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112937","volume":"42","author":"N Tabrizian","year":"2023","unstructured":"Tabrizian N, Nouruzi S, Cui CJ, Kobelev M, Namekawa T, Lodhia I, et al. ASCL1 is activated downstream of the ROR2\/CREB signaling pathway to support lineage plasticity in prostate cancer. Cell Rep. 2023;42:112937.","journal-title":"Cell Rep"},{"key":"1087_CR21","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.21037\/atm-22-4583","volume":"10","author":"X Ge","year":"2022","unstructured":"Ge X, Lin F, Wu Z, Lin Y, Tang W, McKay MJ, et al. Role of ROR2 in promoting gastric cancer metastasis by enhancing c-JUN-mediated MMP3 transcription. Ann Transl Med. 2022;10:1117.","journal-title":"Ann Transl Med"},{"key":"1087_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s13046-021-02187-z","volume":"40","author":"K Menck","year":"2021","unstructured":"Menck K, Heinrichs S, Wlochowitz D, Sitte M, Noeding H, Janshoff A, et al. WNT11\/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer. J Exp Clin Cancer Res. 2021;40:395.","journal-title":"J Exp Clin Cancer Res"},{"key":"1087_CR23","doi-asserted-by":"crossref","unstructured":"Yeh CF, Chan TC, Ke HL, Chen TJ, Wu LC, Lee HY, et al. Prognostic significance of ROR2 expression in patients with urothelial carcinoma. Biomedicines. 2021;9:1054.","DOI":"10.3390\/biomedicines9081054"},{"key":"1087_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111589","volume":"28","author":"F Leng","year":"2025","unstructured":"Leng F, Huang J, Wu L, Zhang J, Lin X, Deng R, et al. Targeting ROR2 homooligomerization disrupts ROR2-dependent signaling and suppresses stem-like cell properties of human breast adenocarcinoma. iScience. 2025;28:111589.","journal-title":"iScience"},{"key":"1087_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1087_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccell.2020.05.014","volume":"38","author":"B Salik","year":"2020","unstructured":"Salik B, Yi H, Hassan N, Santiappillai N, Vick B, Connerty P, et al. Targeting RSPO3-LGR4 signaling for leukemia stem cell eradication in acute myeloid leukemia. Cancer Cell. 2020;38:263\u201378.e266.","journal-title":"Cancer Cell"},{"key":"1087_CR27","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752\u20139.","journal-title":"Blood"},{"key":"1087_CR28","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2005-06-2248","volume":"106","author":"S Schnittger","year":"2005","unstructured":"Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733\u20139.","journal-title":"Blood"},{"key":"1087_CR29","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","volume":"106","author":"K D\u00f6hner","year":"2005","unstructured":"D\u00f6hner K, Schlenk RF, Habdank M, Scholl C, R\u03cbcker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740\u20136.","journal-title":"Blood"},{"key":"1087_CR30","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1600-0609.2007.01019.x","volume":"80","author":"S Scholl","year":"2008","unstructured":"Scholl S, Theuer C, Scheble V, Kunert C, Heller A, M\u00fcgge L-O, et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 years with acute myeloid leukemia. Eur J Haematol. 2008;80:208\u201315.","journal-title":"Eur J Haematol"},{"key":"1087_CR31","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","volume":"107","author":"C Thiede","year":"2006","unstructured":"Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011\u201320.","journal-title":"Blood"},{"key":"1087_CR32","doi-asserted-by":"crossref","unstructured":"Shin DY. TP53 mutation in acute myeloid leukemia: an old foe revisited. Cancers. 2023;15:4816.","DOI":"10.3390\/cancers15194816"},{"key":"1087_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3324\/haematol.2011.051532","volume":"97","author":"M Pratcorona","year":"2012","unstructured":"Pratcorona M, Abbas S, Sanders MA, Koenders JE, Kavelaars FG, Erpelinck-Verschueren CA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012;97:388\u201392.","journal-title":"Haematologica"},{"key":"1087_CR34","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u201364.e859.","journal-title":"Cancer Cell"},{"key":"1087_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300445","volume":"10","author":"G Liang","year":"2023","unstructured":"Liang G, Wang L, You Q, Cahill K, Chen C, Zhang W, et al. Cellular composition and 5hmC signature predict the treatment response of AML patients to azacitidine combined with chemotherapy. Adv Sci. 2023;10:e2300445.","journal-title":"Adv Sci"},{"key":"1087_CR36","doi-asserted-by":"crossref","unstructured":"John M, C Ford E. Pan-tissue and cancer analysis of ROR1 and ROR2 transcript variants identify novel functional significance for an alternative splice variant of ROR1. Biomedicines. 2022;10:2559.","DOI":"10.3390\/biomedicines10102559"},{"key":"1087_CR37","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood.2021013201","volume":"139","author":"ML Amaya","year":"2022","unstructured":"Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022;139:584\u201396.","journal-title":"Blood"},{"key":"1087_CR38","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1172\/JCI120156","volume":"128","author":"A Shastri","year":"2018","unstructured":"Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018;128:5479\u201388.","journal-title":"J Clin Invest"},{"key":"1087_CR39","doi-asserted-by":"crossref","unstructured":"Fuertes G, Del Valle-P\u00e9rez B, Pastor J, Andrades E, Pe\u00f1a R, Garc\u00eda de Herreros A, et al. Noncanonical Wnt signaling promotes colon tumor growth, chemoresistance and tumor fibroblast activation. EMBO Rep. 2023;24:e54895.","DOI":"10.15252\/embr.202254895"},{"key":"1087_CR40","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/jcmm.16233","volume":"25","author":"Y Dai","year":"2021","unstructured":"Dai Y, Cheng Z, Fricke DR, Zhao H, Huang W, Zhong Q, et al. Prognostic role of Wnt and Fzd gene families in acute myeloid leukaemia. J Cell Mol Med. 2021;25:1456\u201367.","journal-title":"J Cell Mol Med"},{"key":"1087_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"1087_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fonc.2020.00262","volume":"10","author":"R Epperly","year":"2020","unstructured":"Epperly R, Gottschalk S, Velasquez MP. A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy. Front Oncol. 2020;10:262.","journal-title":"Front Oncol"},{"key":"1087_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","volume":"15","author":"Z Ying","year":"2019","unstructured":"Ying Z, He T, Wang X, Zheng W, Lin N, Tu M, et al. Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B-cell non-Hodgkin\u2019s lymphoma. Mol Ther Oncolytics. 2019;15:60\u20138.","journal-title":"Mol Ther Oncolytics"},{"key":"1087_CR44","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3892\/or.14.1.291","volume":"14","author":"M Katoh","year":"2005","unstructured":"Katoh M, Katoh M. Comparative genomics on ROR1 and ROR2 orthologs. Oncol Rep. 2005;14:1381\u20134.","journal-title":"Oncol Rep"},{"key":"1087_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102400","volume":"6","author":"J Weber","year":"2025","unstructured":"Weber J, Rade M, Michael J, Tony LT, Freitag F, Spieler P, et al. ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. Cell Rep Med. 2025;6:102400.","journal-title":"Cell Rep Med"},{"key":"1087_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254\u201366.","journal-title":"N Engl J Med"},{"key":"1087_CR47","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1087_CR48","doi-asserted-by":"crossref","unstructured":"Yu J, Sun J, Du Y, Patel R, Varela JC, Mori S, et al. Adverse impact of DNA methylation regulatory gene mutations on the prognosis of AML patients in the 2017 ELN favorable risk group, particularly those defined by NPM1 mutation. Diagnostics. 2021;11:986.","DOI":"10.3390\/diagnostics11060986"},{"key":"1087_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-170","volume":"9","author":"E Lara","year":"2010","unstructured":"Lara E, Calvanese V, Huidobro C, Fern\u00e1ndez AF, Moncada-Pazos A, Obaya AJ, et al. Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol Cancer. 2010;9:170.","journal-title":"Mol Cancer"},{"key":"1087_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101137","volume":"61","author":"Z King","year":"2025","unstructured":"King Z, Desai SR, Frank DA, Shastri A. STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes. Neoplasia. 2025;61:101137.","journal-title":"Neoplasia"},{"key":"1087_CR51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3892\/ol.2025.14881","volume":"29","author":"H Cheng","year":"2025","unstructured":"Cheng H, Chen L, Huang C. Advances of signal transducer and activator of transcription 3 inhibitors in acute myeloid leukemia (Review). Oncol Lett. 2025;29:134.","journal-title":"Oncol Lett"},{"key":"1087_CR52","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41375-026-02883-9","volume":"40","author":"S Chakraborty","year":"2026","unstructured":"Chakraborty S, Morganti C, Zaldana K, Rivera Pena B, Zhang H, Verma D, et al. A STAT3 degrader demonstrates efficacy in venetoclax-resistant acute myeloid leukemia. Leukemia. 2026;40:717\u201329.","journal-title":"Leukemia"},{"key":"1087_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.659253","volume":"11","author":"N van Gils","year":"2021","unstructured":"van Gils N, Denkers F, Smit L. Escape from treatment: the different faces of leukemic stem cells and therapy resistance in acute myeloid leukemia. Front Oncol. 2021;11:659253.","journal-title":"Front Oncol"},{"key":"1087_CR54","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108:353\u201366.","journal-title":"Haematologica"},{"key":"1087_CR55","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","volume":"11","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 2021;11:599\u2013613.","journal-title":"Cancer Discov"},{"key":"1087_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68359-x","volume":"14","author":"JG Lim","year":"2024","unstructured":"Lim JG, Park SJ, Lee SM, Jeong Y, Kim J, Lee S, et al. Hybrid CMOS-Memristor synapse circuits for implementing Ca ion-based plasticity model. Sci Rep. 2024;14:17915.","journal-title":"Sci Rep"},{"key":"1087_CR57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"G Stemer","year":"2021","unstructured":"Stemer G, Rowe JM, Ofran Y. Efficacy and safety profile of ivosidenib in the management of patients with acute myeloid leukemia (AML): an update on the emerging evidence. Blood Lymphat Cancer. 2021;11:41\u201354.","journal-title":"Blood Lymphat Cancer"},{"key":"1087_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","volume":"12","author":"H Ma","year":"2019","unstructured":"Ma H, Padmanabhan IS, Parmar S, Gong Y. Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol. 2019;12:41.","journal-title":"J Hematol Oncol"},{"key":"1087_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100751","volume":"31","author":"JC Boucher","year":"2023","unstructured":"Boucher JC, Shrestha B, Vishwasrao P, Leick M, Cervantes EV, Ghafoor T, et al. Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Ther Oncolytics. 2023;31:100751.","journal-title":"Mol Ther Oncolytics"},{"key":"1087_CR60","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","volume":"15","author":"S Caruso","year":"2022","unstructured":"Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;15:163.","journal-title":"J Hematol Oncol"},{"key":"1087_CR61","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"1087_CR62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15:88.","journal-title":"J Hematol Oncol"},{"key":"1087_CR63","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3324\/haematol.2014.113092","volume":"100","author":"EM Lee","year":"2015","unstructured":"Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015;100:914\u201326.","journal-title":"Haematologica"},{"key":"1087_CR64","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood.2020009192","volume":"138","author":"H Jetani","year":"2021","unstructured":"Jetani H, Navarro-Bail\u00f3n A, Maucher M, Frenz S, Verbruggen C, Yeguas A, et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood. 2021;138:1830\u201342.","journal-title":"Blood"},{"key":"1087_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1093750","volume":"14","author":"G Wu","year":"2023","unstructured":"Wu G, Guo S, Luo Q, Wang X, Deng W, Ouyang G, et al. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Front Immunol. 2023;14:1093750.","journal-title":"Front Immunol"},{"key":"1087_CR66","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.4049\/jimmunol.154.6.2612","volume":"154","author":"RQ Hintzen","year":"1995","unstructured":"Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, van Lier RA. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol. 1995;154:2612\u201323.","journal-title":"J Immunol"},{"key":"1087_CR67","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2490078","volume":"17","author":"HW Chang","year":"2025","unstructured":"Chang HW, Frey G, Wang J, Liu H, Xing C, Chen J, et al. Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate. MAbs. 2025;17:2490078.","journal-title":"MAbs"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01087-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01087-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01087-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:02:07Z","timestamp":1792605727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01087-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":67,"alternative-id":["1087"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01087-8","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study involving human material (marrow or peripheral blood samples) was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Shenzhen University General Hospital (approval number: 2020-002-02). Written informed consent was obtained from all patients with leukemia and healthy donors prior to the collection of their marrow or peripheral blood samples.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}